Moderna, Inc. (KASE:MRNA_KZ)
Kazakhstan · Delayed Price · Currency is KZT · Price in USD | Market Cap | 46.15T +855.3% |
| Revenue (ttm) | 1.11T +13.1% |
| Net Income | -1.23T |
| EPS | -3,155.93 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54 |
| Open | 236.92 |
| Previous Close | 244.83 |
| Day's Range | 236.87 - 263.18 |
| 52-Week Range | 25.10 - 260.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna price target raised to $260 from $220 at BofA
BofA raised the firm’s price target on Moderna (MRNA) to $260 from $220 and keeps a Neutral rating on the shares after what the firm calls a “clean beat and…
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
British drugmaker GSK has settled lawsuits that accused Moderna's [COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.
Moderna price target raised to $145 from $130 at RBC Capital
RBC Capital raised the firm’s price target on Moderna (MRNA) to $145 from $130 and keeps a Sector Perform rating on the shares.
Moderna price target raised to $110 from $90 at TD Cowen
TD Cowen analyst Tyler Van Buren raised the firm’s price target on Moderna (MRNA) to $110 from $90 and keeps a Hold rating on the shares. “Strong” and balanced U.S.
Moderna Stock (MRNA) Gains After COVID-Fueled Q3 Earnings Beat
Shares in drugs group Moderna ($MRNA) rose in pre-market trading as its Q3 earnings continued to be buoyed by COVID and it upped its full-year revenue forecasts. It said that…
Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.
Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.
Moderna Earnings Call Transcript: Q3 2026
Q3 revenue rose 29% YoY to $1.3B and net income was $162M; FY2026 revenue growth guidance was raised, with lower cash-cost and capex targets. Intismeran delivered positive Phase III melanoma results as respiratory approvals expanded.
Moderna Earnings release: Q3 2026
Moderna released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
Moderna Slides: Q3 2026
Moderna has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 6, 2026.
Moderna Quarterly report: Q3 2026
Moderna has published its Q3 2026 quarterly earnings report on November 6, 2026.
Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit
The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.
Moderna sees year-end 2026 cash and investments $8.1B-$8.3B
The company now expects year-end 2026 cash and investments of approximately $8.1 billion to $8.3 billion, increased from its previous outlook of $4.7 billion to $5.2 billion. The increase reflects…
Moderna up 10% to $267.36 after raising FY26 revenue growth view
07:16 EST Moderna (MRNA) up 10% to $267.36 after raising FY26 revenue growth view
Moderna reports Q3 GAAP diluted EPS 38c vs. (51c) last year
Reports Q3 revenue $1.31B vs. $1.02B last year. “We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive…
Moderna raises FY26 revenue growth view to 15%-25% from 10%
The company now expects total revenue growth of 15% to 25% in 2026, exceeding its previous outlook of up to 10% growth. Moderna (MRNA) continues to expect approximately half of…
Moderna's stock jumps after biotech raises sales outlook
The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
Moderna lifted its full-year revenue forecast on Friday, after strong international demand for its COVID-19 vaccine and payments from partnerships helped the biotech swing to profit in the third qua...
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous...
Moderna announces Health Canada authorization of Flu-Covid vaccine combination
The company states: “Moderna (MRNA) announced that Health Canada has authorized mFLUSIVA (Influenza mRNA vaccine; mRNA-1010) and mCOFLU(R) (Combined Influenza and COVID-19 mRNA vaccine; mRNA-1083) for...
Polymarket Odds: Will MRNA, HUM, UAA Beat Earnings Tomorrow?
On Friday, November 6, Moderna ($MRNA), Humana ($HUM), and Under Armour ($UAA) will report their earnings. All three companies will report before the market opens. Traders are already weighing in…
The Big 3: HCA, ISRG, MRNA
As the AI-centric selloff batters the S&P 500 (SPX) and Nasdaq-100 (NDX), Jason Brown (@brownreport) points to the healthcare sector as a bright spot in a day of stark selling. He focuses on stocks ac...
Moderna advances investigational Bundibugyo ebola vaccine toward Phase 2/3 study
Moderna (MRNA) announced that mRNA-1469, the Company’s investigational mRNA vaccine candidate against Bundibugyo ebolavirus, has been recommended to advance into a Phase 2/3 efficacy study in the Demo...
Moderna announces presentation of data from Phase 1/2 study of mRNA-2808
Moderna (MRNA) announced that initial clinical data from its ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of Hematology, ASH, Annual…
Moderna, Merck eye FDA approval for promising cancer vaccine
Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.'